by
I-Liang Lim, Angela Voon Pei Loo, Visvaraja Subrayan, Tsung Fei Khang, Mee
Hoong See, Adlinda Alip, Nur Aishah Mohd Taib
It is
now increasingly common for breast cancer patients to receive adjuvant
tamoxifen therapy for a period of up to 10 years. As survival rate increases,
managing tamoxifen ocular toxicities is important for patients' quality of
life. Macular pigments in photoreceptor cells protect against free radical
damage, which can cause macular degeneration. By reducing macular pigment
concentration, tamoxifen may increase the risk of macular degeneration. Here,
we compared macular pigment optical density (MPOD) and central macular
thickness between breast cancer patients on tamoxifen adjuvant therapy
(n = 70), and a control group (n = 72).
